Table 3:

Factors Associated with consistent (≥ 30 days/year) Inappropriate and Potentially Inappropriate Medication Use

	NSAID Use	Opiate Use	Benzodiazepine Use	PPI Use
	OR (95% CI)
Gender (Male)	0.6 (0.5–0.8) p<0.001	0.9 (0.8–0.97) p=0.006	0.7 (0.6–0.8) p<0.001	1.0 (0.9–1.1) p=0.667
Age at first liver decompensation	1.00 (0.99–1.01) p=0.563	0.99 (0.98–0.99) p<0.001	0.97 (0.97–0.98) p<0.001	1.02 (1.01–1.02) p<0.001
Race/Ethnicity
White	1.0 (0.6–1.7) p=0.972	1.0 (0.8–1.2) p=0.975	1.1 (0.8–1.5) p=0.696	1.0 (0.8–1.2) p=0.838
Hispanic	0.9 (0.5–1.6) p=0.629	0.8 (0.6–1.0) p=0.094	0.6 (0.4–0.9) p=0.006	1.1 (0.9–1.4) p=0.397
African American	1.2 (0.7–2.3) p=0.511	1.0 (0.8–1.3) p=0.876	0.8 (0.5–1.2) p=0.226	0.9 (0.7–1.1) p=0.289
Asian	0.8 (0.3–2.0) p=0.654	0.4 (0.3–0.6) p<0.001	0.5 (0.2–0.9) p=0.023	0.9 (0.6–1.2) p=0.317
Co-morbid Conditions
Peptic Ulcer Disease				1.7 (1.6–1.9) p<0.001
Gastroesophageal Reflux				2.3 (2.1–2.5) p<0.001
Dyspepsia				1.2 (1.1–1.4) p=0.008
Inpatient Codes
Inpatient Ascites Diagnosis	0.7 (0.6–0.9) p=0.009
Inpatient HE		1.3 (1.2–1.5)	1.0 (0.8–1.1)
Diagnosis		p<0.001	p=0.683
Procedures
Rx after TIPS*		0.6 (0.3–0.98) p=0.045	1.9 (0.7–5.8) p=0.234
Rx after Paracentesis**	0.8 (0.5–1.1) p=0.141
Paracentesis # During Follow up	0.9 (0.8–0.97) p=0.008
Gastroenterology or Hepatology Provider Consultation	0.9 (0.7–1.1) p=0.318	1.1 (0.99–1.2) p=0.056	1.2 (0.99–1.4) p=0.073	1.7 (1.5–1.8) p<0.001

HE: Hepatic Encephalopathy

PPI: Proton Pump Inhibitor

NSAID: Non-Steroidal Anti-Inflammatory Drug

TIPS: Transjugular Intrahepatic Portosystemic Shunt

^*Medication use after TIPS for those who underwent TIPS compared to medication use for those who did not undergo TIPS

^**Medication use after paracentesis compared to medication use for those who did not undergo paracentesis